Gut Peptides as Obesity Drugs: GLP-1, PYY, Ghrelin, and Others as Therapeutic Targets

Gut peptides including GLP-1, PYY, oxyntomodulin, and ghrelin are the most promising peripheral targets for obesity pharmacotherapy, with GLP-1 agonists leading clinical development.

Scharf, Matthew T et al.·Seminars in liver disease·2004·Moderate EvidenceReview
RPEP-00973ReviewModerate Evidence2004RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Gut peptide-based obesity drugs including GLP-1 agonists, PYY analogs, oxyntomodulin, and ghrelin antagonists represent the most promising peripheral anti-obesity targets, with GLP-1 showing the most advanced clinical development.

Key Numbers

How They Did This

review study on glp-1, ghrp.

Why This Research Matters

Relevant for glp-1, ghrp, weight-loss, gut-healing.

The Bigger Picture

Advances peptide therapeutics research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding Gut peptide-based obesity drugs including GLP-1 agonists, PYY analogs, oxyntomodulin, and ghrelin antagonists represent the most promising peripheral
Evidence Grade:
moderate evidence.
Study Age:
Published in 2004.
Original Title:
Gut peptides and other regulators in obesity.
Published In:
Seminars in liver disease, 24(4), 335-47 (2004)
Database ID:
RPEP-00973

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What was studied?

Gut Peptides as Obesity Drugs: GLP-1, PYY, Ghrelin, and Others as Therapeutic Targets

What was found?

Gut peptides including GLP-1, PYY, oxyntomodulin, and ghrelin are the most promising peripheral targets for obesity pharmacotherapy, with GLP-1 agonists leading clinical development.

Read More on RethinkPeptides

Cite This Study

RPEP-00973·https://rethinkpeptides.com/research/RPEP-00973

APA

Scharf, Matthew T; Ahima, Rexford S. (2004). Gut peptides and other regulators in obesity.. Seminars in liver disease, 24(4), 335-47.

MLA

Scharf, Matthew T, et al. "Gut peptides and other regulators in obesity.." Seminars in liver disease, 2004.

RethinkPeptides

RethinkPeptides Research Database. "Gut peptides and other regulators in obesity." RPEP-00973. Retrieved from https://rethinkpeptides.com/research/scharf-2004-gut-peptides-and-other

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.